DNA alkylation products formed by 1-(2-chloroethyl)-1-nitrosourea as molecular dosimeters of therapeutic response

Journal of Neuro-Oncology

Volumn 91, Issue 3, 2009, Pages 257-264

  Bodell, William J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Contrast Therapeutics ^*  (United States)

Author keywords

BCNU; DNA adducts; Drug delivery; Molecular dosimeter; Therapeutic response

Indexed keywords

1 (N 1,2 DEOXYGUANOSINYL) 2 (N 2,3 DEOXYCYTIDYL)ETHANE; 1,2 (DIGUAN 7 YL) ETHANE; 6 O (2 CHLOROXYETHYL) 2 DEOXYGUANOSINE; 6 O (2 HYDROXYETHYL) 2 DEOXYGUANOSINE; 7 (2 HYDROXYETHYL)GUANINE; BIOLOGICAL MARKER; CARMUSTINE; CHLOROETHYLNITROSOUREA; METHYLNITROSOUREA; N 1 (2 HYDROXYETHYL) 2 DEOXYGUANOSINE; N 7 (2 CHLOROETHYL)GUANINE; TRITIUM; UNCLASSIFIED DRUG;

ARTICLE; CELL SURVIVAL; CELL VIABILITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DNA ADDUCT; DNA ALKYLATION; DNA CROSS LINKING; DOSIMETRY; GLIOMA; HUMAN; HUMAN CELL; LETHAL DOSE; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE;

ALKYLATION; ANTINEOPLASTIC AGENTS, ALKYLATING; CARMUSTINE; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA ADDUCTS; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; ETHYLNITROSOUREA; GLIOMA; HUMANS; STATISTICS AS TOPIC; TUMOR SUPPRESSOR PROTEINS;

EID: 58149476199     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-008-9715-1     Document Type: Article

References (40)

1. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ et al (1993) Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 85:704-710. doi: 10.1093/jnci/85.9.704
2. Spiegel BM, Esrailian E, Laine L, Chamberlain MC (2007) Clinical impact of adjuvant chemotherapy in glioblastoma multiforme: A meta-analysis. CNS Drugs 21:775-787. doi: 10.2165/00023210-200721090-00006
3. Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B et al (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: Recursive partitioning analysis of the EORTC 26981/ 22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563-2569. doi: 10.1200/JCO.2005.04.5963
4. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, Network GermanGlioma et al (2007) Long-term survival with glioblastoma multiforme. Brain 130:2596-2606. doi: 10.1093/brain/awm204
5. Deeken JF, Loscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and trojan horses. Clin Cancer Res 13:1663-1674. doi: 10.1158/1078-0432.CCR-06-2854
6. Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR et al (2007) Chemotherapy delivery issues in central nervous system malignancy: A reality check. J Clin Oncol 25:2295-2305. doi: 10.1200/ JCO.2006.09.9861
7. Groothuis DR (2000) The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery. Neuro Oncol 2:45-59. doi: 10.1215/15228517-2-1-45
8. Steinbach JP, Weller M (2004) Apoptosis in gliomas: Molecular mechanisms and therapeutic implications. J Neurooncol 70:245-254. doi: 10.1007/ s11060-004-2753-4
9. Salhia B, Tran NL, Symons M, Winkles JA, Rutka JT, Berens ME (2006) Molecular pathways triggering glioma cell invasion. Expert Rev Mol Diagn 6:613-626. doi: 10.1586/14737159.6.4.613
10. Guha A, Mukherjee J (2004) Advances in the biology of astrocytomas. Curr Opin Neurol 17:655-662. doi: 10.1097/00019052-200412000-00004
11. Weingart J, Grossman SA, Carson KA, Fisher JD, Delaney SM, Rosenblum ML et al (2007) Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: New approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 25:399-404. doi: 10.1200/JCO.2006.06.6290
12. Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79-88. doi: 10.1215/15228517-5-2-79
13. Bodell WJ, Bodell AP, Giannini DD (2007) Levels and distribution of BCNU in GBM tumors following intratumoral injection of DTI-015 (BCNU-ethanol). Neuro Oncol 9:12-19. doi: 10.1215/15228517-2006-014
14. Hassenbusch SJ, Nardone EM, Levin VA, Leeds N, Pietronigro D (2003) Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial. Neoplasia 5:9-16
15. Bodell WJ, Giannini DD, Hassenbusch S, Levin VA (2001) Levels of N7-(2-hydroxyethyl)guanine as a molecular dosimeter of drug delivery to human brain tumors. Neuro Oncol 3:241-245. doi: 10.1215/15228517-3-4-241
16. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM et al, Cintredekin Besudotox Intraparenchymal Study Group (2007) Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: A report by the cintredekin besudotox intraparenchymal study group. J Clin Oncol 25:837-844. doi: 10.1200/ JCO.2006.08.1117
17. Parney IF, Kunwar S, McDermott M, Berger M, Prados M, Cha S et al (2005) Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 102:267-275
18. Lidar Z, Mardor Y, Jonas T, Pfeffer R, Faibel M, Nass D et al (2004) Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: A phase I/II clinical study. J Neurosurg 100:472-479
19. Ali MJ, Navalitloha Y, Vavra MW, Kang EW, Itskovich AC, Molnar P et al (2006) Isolation of drug delivery from drug effect: Problems of optimizing drug delivery parameters. Neuro Oncol 8:109-118. doi: 10.1215/ 15228517-2005-007
20. Navalitloha Y, Schwartz ES, Groothuis EN, Allen CV, Levy RM, Groothuis DR (2006) Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumors. Neuro Oncol 8:227-233. doi: 10.1215/ 15228517-2006-007
21. Vavra M, Ali MJ, Kang EW, Navalitloha Y, Ebert A, Allen CV et al (2004) Comparative pharmacokinetics of 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery. Neuro Oncol 6:104-112. doi: 10.1215/S1152851703000449
22. Levin VA (1980) Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 23:682-684. doi: 10.1021/jm00180a022
23. Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kortmann RD et al (2006) Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24:4412-4417. doi: 10.1200/JCO.2006.06.9104
24. Souhami L, Seiferheld W, Brachman D, Podgorsak EB, Werner-Wasik M, Lustig R et al (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of radiation therapy oncology group 93-05 protocol. Int J Radiat Oncol Biol Phys 60:853-860. doi: 10.1016/j.ijrobp.2004.04.011
25. Levin VA, Uhm JH, Jaeckle KA, Choucair A, Flynn PJ, Yung WKA et al (2000) Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 6:3878-3884
26. Ludlum DB (1990) DNA alkylation by the haloethylnitrosoureas: Nature of modifications produced and their enzymatic repair or removal. Mutat Res 233:117-126. doi: 10.1016/0027-5107(90)90156-X
27. Ye Q, Bodell WJ (1997) Detection of N7-(2-hydroxyethyl)guanine adducts in DNA and 9L cells treated with 1-(2-chloroethyl)-1-nitrosourea. J Chromatogr B Biomed Sci Appl 694:65-70. doi: 10.1016/ S0378-4347(97)00161-8
28. Bodell WJ, Giannini DD, Singh S, Pietronigro D, Levin VA (2003) Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015. J Neurooncol 62:251-258. doi: 10.1023/ A:1023383717833
29. Darcy KM, Tian C, Reed E (2007) A gynecologic oncology group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res 67:4474-4481. doi: 10.1158/ 0008-5472.CAN-06-4076
30. Hoebers FJ, Pluim D, Verheij M, Balm AJ, Bartelink H, Schellens JH et al (2006) Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT). Int J Cancer 119:750-756. doi: 10.1002/ijc.21919
31. van de Vaart PJ, Belderbos J, de Jong D, Sneeuw KC, Majoor D, Bartelink H et al (2000) DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 89:160-166 10.1002/ (SICI)1097-0215(20000320)89:2<160::AID-IJC10>3.0.CO;2-J
32. Bodell WJ, Tokuda K, Ludlum DB (1988) Differences in DNA alkylation products formed in sensitive and resistant human glioma cells treated with N-(2-chloroethyl)-N-nitrosourea. Cancer Res 48:4489-4492
33. Bodell WJ (2003) Repair of DNA alkylation products formed in 9L cell lines treated with 1-(2-chloroethyl)-1-nitrosourea. Mutat Res 522:85-92. doi: 10.1016/S0027-5107(02)00262-2
34. Bodell WJ (1999) Effect of cations on the formation of DNA alkylation products in DNA reacted with 1-(2-chloroethyl)-1-nitrosourea. Chem Res Toxicol 12:965-970. doi: 10.1021/tx980200c
35. Bodell WJ, Pongracz K (1993) Chemical synthesis and detection of the cross-link 1-[N3-(2′-deoxycytidyl)]-2-[N1-(2′-deoxyguanosinyl)]ethane in DNA reacted with 1-(2-chloroethyl)-1-nitrosourea. Chem Res Toxicol 6:434-438. doi: 10.1021/tx00034a008
36. Rabik CA, Njoku MC, Dolan ME (2006) Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev 32:261-276. doi: 10.1016/j.ctrv.2006.03.004
37. Gerson SL (2004) MGMT: Its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296-307. doi: 10.1038/nrc1319
38. Tong WP, Kirk MC, Ludlum DB (1982) Formation of the cross-link 1-[N3-deoxycytidyl), 2-[N1-deoxyguanosinyl]ethane in DNA treated with N, N′-bis(2-chloroethyl)-N-nitrosourea. Cancer Res 42:3102-3105
39. Parker S, Kirk MC, Ludlum DB (1987) Synthesis and characterization of O6-(2-chloroethyl)guanine: A putative intermediate in the cytotoxic reaction of chloroethylnitrosoureas with DNA. Biochem Biophys Res Commun 148:1124-1128. doi: 10.1016/S0006-291X(87)80249-8
40. Aida T, Cheitlin RA, Bodell WJ (1987) Inhibition of O6-alkylguanine-DNA-alkyltransferase activity potentiates cytotoxicity and induction of SCEs in human glioma cells resistant to 1, 3-bis(2-chloroethyl)-1-nitrosourea. Carcinogenesis 8:1219-1223. doi: 10.1093/carcin/8.9.1219